Vicore Pharma Holding AB
NASDAQTotal Valuation
Vicore Pharma Holding AB carries a market capitalization of 3.88B, placing it among publicly traded companies globally. Its enterprise value stands at -1.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.88B |
| Enterprise Value | -1.06B |
Share Statistics
Vicore Pharma Holding AB currently has 281.53M shares outstanding.
| Shares Outstanding | 281.53M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Vicore Pharma Holding AB maintains a current ratio of 12.69, meaning it holds 12.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.69 |
| Quick Ratio | 12.52 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -15.56 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -33.42 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 86,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Vicore Pharma Holding AB's stock has declined approximately -15.2% over the past 52 weeks. The 50-day moving average sits at 14.63, while the 200-day moving average is 14.63.
| Beta (5Y) | N/A |
| 52-Week Price Change | -15.2% |
| 50-Day Moving Average | 14.63 |
| 200-Day Moving Average | 14.63 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Vicore Pharma Holding AB generated 2.77M in revenue and converted that into -361.08M in net income, yielding earnings per share of -1.44. EBITDA reached -368.72M, while operating income came in at -368.72M.
| Revenue | 2.77M |
| Gross Profit | 2.77M |
| Operating Income | -368.72M |
| Pretax Income | -361.00M |
| Net Income | -361.08M |
| EBITDA | -368.72M |
| EBIT | -368.72M |
| Earnings Per Share (EPS) | -1.44 |
Balance Sheet
| Cash & Cash Equivalents | 1.06B |
| Total Debt | N/A |
| Net Debt | -377.42M |
| Equity (Book Value) | N/A |
| Book Value Per Share | N/A |
| Working Capital | 989.59M |
Cash Flow
Vicore Pharma Holding AB produced -305.57M in operating cash flow over the past twelve months.
| Operating Cash Flow | -305.57M |
| Capital Expenditures | N/A |
| Free Cash Flow | -305.57M |
| FCF Per Share | -1.21 |
Margins
Vicore Pharma Holding AB operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -13,325.73 and net profit margin of -13,049.58 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -13,325.73 |
| Pretax Margin | -13,046.48 |
| Profit Margin | -13,049.58 |
| EBITDA Margin | -13,325.73 |
Scores
Vicore Pharma Holding AB posts an Altman Z-Score of -0.02, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.02 |